Tarsus Pharmaceuticals saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 80 to 87.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's unique RS Rating tracks technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
History reveals that the market's biggest winners tend to have an 80 or better RS Rating in the early stages of their moves.
While Tarsus Pharmaceuticals is not near a proper buy point right now, see if it is able to form and break out from a proper chart pattern.
Tarsus Pharmaceuticals showed 0% earnings growth in its most recent report. Revenue rose 184%.
The company holds the No. 75 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and ADMA Biologics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
